Treatment of Small Bowel Adenocarcinoma with 5-Fluorouracil
Author Information
Author(s): C Crawley, P Ross, A Norman, A Hill, D Cunningham
Primary Institution: Royal Marsden Hospital
Hypothesis
The study aims to review the efficacy of protracted venous infusion of 5-fluorouracil-based chemotherapy in advanced small bowel adenocarcinoma.
Conclusion
PVI 5-FU has activity in advanced small bowel adenocarcinoma and is well tolerated.
Supporting Evidence
- Three out of eight patients showed a response to the treatment, resulting in a response rate of 37.5%.
- The median overall survival for patients was 13 months.
- Patients experienced symptomatic benefits, with improvements in quality of life.
Takeaway
Doctors gave a special medicine called 5-FU to eight people with a type of stomach cancer, and it helped some of them feel better and live longer.
Methodology
Data on all patients with small bowel malignancy seen at the Royal Marsden Hospital over a 5-year period were reviewed, and responses were assessed according to WHO criteria.
Limitations
The study is based on a small sample size from a single institution.
Participant Demographics
The study included eight patients with advanced small bowel adenocarcinoma, with varying ages and prior medical histories.
Want to read the original?
Access the complete publication on the publisher's website